Mechanism of action

Fintepla (fenfluramine) – offering a new standard in Dravet syndrome seizure control

Fintepla is a new, adjunctive treatment for seizures associated with Dravet syndrome for patients 2 years of age and older.
The unique mode of action of Fintepla targets the serotonergic system and sigma-1 receptors.1

Effect of fenfluramine on the serotonergic system

Fenfluramine may reduce seizures partly by acting as a serotonin releaser into the synapse,2,3 by disrupting vesicular storage of the neurotransmitter, inhibiting the serotonin transporter4 and as an agonist at specific serotonin receptors in the brain, including 5-HT1D, 5-HT2A and 5-HT2C. 2

effect of fenfluramine on the serotonergic system
effect of fenfluramine on the serotonergic system

Effect of fenfluramine on sigma-1 receptors

Fenfluramine may also reduce seizures through its activity as a positive modulator of the sigma-1 receptor.5

Fintepla is a selective serotonin (5-HT)-releasing agent4


  • Stimulates multiple 5-HT receptor subtypes through the release of serotonin

Fintepla may reduce seizures by:1


  • Acting as an agonist at specific serotonin receptors in the brain
  • Acting on the sigma-1 receptor

Fintepla may also act through other mechanisms not yet identified in reducing seizures1

The exact mechanism by which Fintepla exerts its therapeutic effects in the treatment of seizures in Dravet syndrome is unknown.1

View references

  1. Fintepla Summary of Product Characteristics. 

Adverse events should be reported.

Please refer to section 4.8 of the SmPC for national reporting requirements in your country.

Adverse events should also be reported to Zogenix International Limited on +44 (0)800 060 8767 or email medinfo.eu@zogenix.com